Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics and the emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world. While the company provides some of the most technologically advanced products in the industry, everything is driven by the fundamental belief that “the beauty of science is to make things simple.”
UNLV Office of Technology Transfer and Economic Development
UNLV is Nevada’s premier public research university and a powerhouse for groundbreaking discovery and innovation, particularly in life sciences and biotechnology. At the forefront of UNLV’s industry and business engagement are our dynamic offices of Economic Development and Technology Transfer, serving as vital connectors between pioneering research and impactful commercialization opportunities. UNLV’s cutting-edge Brain Health Department as well as the innovative Wastewater Surveillance Laboratory exemplify our bold approach to solving complex health and environmental challenges. Researchers at these centers drive groundbreaking advancements with profound implications for neuroscience, public health, environmental monitoring, and disease prevention. Uniquely situated within a collaborative and vibrant regional ecosystem, UNLV thrives alongside major stakeholders committed to ambitious, strategic coordination and innovative thinking. This environment enables business and industry partnerships to flourish, supported by open communication and outside-the-box planning that accelerate shared success. At BIO International 2025, our goal is clear: to connect industry leaders, visionaries, and partners directly with UNLV’s exceptional talent, transformative research capabilities, and rich pipeline of licensable technologies. Opportunities abound at UNLV for collaborative sponsored research, tailored workforce development programs, robust startup incubation support, and access to patented university technologies poised for commercialization. Discover how partnering with UNLV can propel your organization’s priorities forward through innovative solutions and collaborations. Connect with us at BIO to harness the full potential of our research excellence and vibrant innovation ecosystem. | UNLV, a Carnegie R1 research institution, is a key player in the delegation’s efforts. UNLV emphasizes industry engagement through opportunities for students, strong bio research, innovation, a collaborative research and technology park, and commercialization of life-changing products in fields like life science, physical science, and engineering. UNLV is seeking to connect with BIOtech companies and explore collaboration opportunities.
Propharma
At ProPharma, we help pharmaceutical, biotechnology, and medical device companies bring life-changing therapies to market. From early development through clinical, regulatory approval, and commercialization, we provide expert guidance to navigate complex challenges and accelerate success. Our mission is simple – improving patient health and safety by delivering the highest quality regulatory, compliance, clinical research, pharmacovigilance, and medical information services throughout the entire product lifecycle. | For over 25 years, ProPharma has partnered with biotech, pharmaceutical, and medical device organizations to bring groundbreaking therapies to market. Offering a fully customizable, end-to-end suite of services, we empower our clients to overcome regulatory complexities and deliver life-changing therapies to patients worldwide. At ProPharma, we help pharmaceutical, biotechnology, and medical device companies bring life-changing therapies to market. From early development through clinical, regulatory approval, and commercialization, we provide expert guidance to navigate complex challenges and accelerate success. Our mission is simple – improving patient health and safety by delivering the highest quality regulatory, compliance, clinical research, pharmacovigilance, and medical information services throughout the entire product lifecycle.
Pharmigene Inc
Established in 2005, Pharmigene Inc. is a leading biotechnology company specializing in pharmacogenomic testing. We hold exclusive global licenses from Academia Sinica for patents related to genetic testing for Warfarin and other critical medications such as Carbamazepine and Allopurinol. Leveraging these proprietary technologies, we have developed advanced diagnostic products and tools that have secured comprehensive technical patent certifications across numerous countries worldwide, including the USA, Europe, New Zealand, Australia, Japan, China, India, and Southeast Asia.Headquartered in Taiwan, Pharmigene operates a state-of-the-art R&D center and maintains stringent quality management systems. Our commitment to excellence is underscored by our certifications, including international ISO 13485, Taiwan QMS (GMP), and South Korea KGMP, ensuring the highest standards in medical device manufacturing and diagnostic solutions.
Molecule 46 s.r.o.
Molecule 46 is a biotech spin-off offering a unique patented technology for the separation of undamaged sperm to be used in human assisted reproduction and solve the infertility problem related to poor sperm quality. This technology is equally applicable to animal breeding strategies. The company brings an innovative approach with a strong IP position and robust scientific research. The new technology and clear regulatory pathway are strengthened by an internationally recognised founder with a strong academic track record and founder/market fit for a large and fast-growing market. Molecule 46 offers real social impact as well as endorsement from buyers and users. Our vision: Separation of winning sperm in alliance with nature. Our aim: Product certification and penetration to all the markets – European, American, and Global. | x
MilliporeSigma
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is committed to advancing cancer research. Our extensive portfolio of over 300,000 products supports the development of novel therapies, diagnostics, and prevention strategies. We offer solutions across key areas, including molecular tools, sample preparation, antibodies, cell culture, live cell analysis, biochemicals, and biomarker immunoassays. Cancer research is a multidisciplinary effort, and we provide integrated tools that accelerate progress at every stage—from basic to clinical research. Our molecular tools allow researchers to study cancer’s genetic and molecular foundations, while our high-quality antibodies enable the detection of proteins involved in cancer progression. MilliporeSigma also offers advanced sample preparation technologies for analyzing DNA, RNA, and proteins from tumor samples, and live cell analysis platforms for real-time insights into cellular behaviors and drug responses. Our biomarker immunoassays help identify cancer biomarkers and monitor treatment efficacy, supporting the development of early detection tests and personalized medicine. We are dedicated to empowering researchers with innovative solutions that help advance cancer prevention, detection, and treatment. MilliporeSigma is your trusted partner in tackling cancer biology complexities, accelerating breakthroughs, and realizing a future where cancer is more treatable and preventable. | As a leading science and technology company, we uniquely combine three specialized, innovation-driven businesses: Life Science, Healthcare, and Electronics. We utilize our multi-industry expertise to address a wide spectrum of global challenges. By supplying advanced scientific research and biotechnological manufacturing products, developing therapies for serious diseases, and providing high-performance materials for semiconductors and displays, we contribute to improving health, scientific progress, and technology for people around the world. | MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany. We are built to serve you in your drug development journey – as one trusted partner. Whether you need Millipore® CTDMO services, with decades of development, manufacturing, and testing expertise, to deliver a streamlined experience, or standalone industry-leading BioReliance® contract testing services and analytical development, we are built to serve you – to accelerate your milestones and breakthroughs. | MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, leverages over 35 years of CDMO experience and 75 years of contract testing services to redefine the industry CDMO model for today’s dynamic market needs. Our integrated Millipore® CTDMO Services offer expertise in development, manufacturing, contract testing, and technologies from pre-clinical to commercial stages, serving as a single experienced partner to accelerate your milestones and breakthroughs. With extensive experience in mRNA & LNP Formulation, ADC, Small Molecule, Biologics, and Viral Vector, we are dedicated to supporting your drug development journey as a trusted partner. Whether you seek a streamlined experience with a single partner or standalone industry-leading BioReliance® contract testing services and analytical development, we are committed to accelerating your milestones and breakthroughs while forging partnerships aimed at bringing breakthroughs to life to ultimately help patients. 2025 North America Advance Biotech Grant Award Ceremony Join us in the Start-up Stadium at 1:30pm, June 17th, to hear from our finalists and discover who will receive $258,000 in bioprocessing technologies, bioprocessing consulting services, contract testing services, and a full subscription to Emprove® Premium. The next round of applications will open in early 2026. | From the first spark of discovery to full-scale manufacturing, we stand beside you with the products, services, and expertise to help you move with speed and confidence. As a global leader in life science, MilliporeSigma supports innovators across biotech and pharma with 300,000+ products and comprehensive solutions all designed to help you progress from early research through process development, scale-up, and manufacturing. What you can explore with us: • Lab essentials and workflows to keep research moving day to day • Water purification systems for consistent lab performance • Raw and starting materials to support reliable manufacturing • Bioprocessing solutions and customized systems for your unique process needs • Ultrafiltration and downstream technologies to support scalable production • Contract testing and CDMO services to help you advance programs and meet quality requirements Whether you’re advancing a lead candidate, scaling a platform, or strengthening manufacturing readiness, we’ll connect you with experts who can help. | MilliporeSigma, the U.S. life science business of Merck KGaA, Darmstadt, Germany, partners with food safety teams to enable you to improve lab testing efficiencies with reliable products and services that meet ever changing regulations. It is through our collaborations that we can advance the safety and analysis of foods and beverages using trusted brands like Millipore® with microbiology solutions for hygiene, environmental monitoring & pathogen detection, Supelco® analytical solutions for analysis of food contamination and authenticity, Milli-Q® lab water solutions and Sigma Aldrich lab & production materials, including chemicals, inorganics & solvents throughout the supply chain, manufacturing and distribution. | MilliporeSigma is the U.S. life science business of Merck KGaA, Darmstadt, Germany. MilliporeSigma’s portfolio spans more than 300,000 products enabling scientific discovery. MilliporeSigma has customers in life science companies, university and government institutions, hospitals and industry. More than 1 million scientists and technologists use its products. The company is committed to solving the toughest problems in life science by collaborating with the global scientific community. | MilliporeSigma is the U.S. life science business of Merck KGaA, Darmstadt, Germany. With 19,000 employees and 72 manufacturing sites worldwide, MilliporeSigma’s portfolio spans more than 300,000 products enabling scientific discovery. MilliporeSigma has customers in life science companies, university and government institutions, hospitals and industry. More than 1 million scientists and technologists use its products. The company is committed to solving the toughest problems in life science by collaborating with the global scientific community. For more information, www.emdmillipore.com and www.sigma-aldrich.com.
iRepertoire
Over the past decade, iRepertoire has developed gold standard technologies for immune repertoire sequencing. Our core technologies provide the ability to amplify expressed V(D)Js in B or T cells, and we offer the only technology that can measure all 7 immune chains simultaneously. We also offer a single cell solution to capture V(D)J rearrangements from rare cell populations. Beyond sequencing, iRepertoire now provides comprehensive data analysis services that accelerate biomarker discovery, advance disease research, and support IO drug development programs. iRepertoire is committed to creating cutting-edge technology and analytical solutions that adapt to the ever-changing immune sequencing landscape. | .